SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-064635
Filing Date
2021-03-02
Accepted
2021-03-02 08:17:01
Documents
14
Period of Report
2021-03-02
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d52747d8k.htm   iXBRL 8-K 25140
2 EX-99.1 d52747dex991.htm EX-99.1 15976
6 GRAPHIC g52747g0302083245604.jpg GRAPHIC 4098
  Complete submission text file 0001193125-21-064635.txt   179038

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA oyst-20210302.xsd EX-101.SCH 3071
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE oyst-20210302_lab.xml EX-101.LAB 18886
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oyst-20210302_pre.xml EX-101.PRE 11860
7 EXTRACTED XBRL INSTANCE DOCUMENT d52747d8k_htm.xml XML 3477
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39112 | Film No.: 21701346
SIC: 2836 Biological Products, (No Diagnostic Substances)